ERBB2 and breast carcinoma: In young women with breast cancer, the pattern of pCR achievement was also subtype-specific, with such an achievement being more frequent in the HER2+ subtype (47%) [12], as shown in another study that evaluated 6337 patients with primary breast cancer treated with NAC from seven randomized trials [7].